TREE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LendingTree is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some favorable valuation and analyst support, but the current technical setup is weak, insider selling is heavy, and there is no recent news catalyst or financial snapshot to justify an aggressive entry. With no AI Stock Picker or SwingMax buy signal present, I would not call this a good buy today. I would wait for a clearer trend reversal and better confirmation from fundamentals before committing capital.
TREE is trading at 35.685, below the pivot level of 37.611 and just above S1 at 35.873, with S2 at 34.799 nearby. MACD histogram is positive at 0.135 but contracting, which suggests momentum is fading rather than strengthening. RSI_6 at 34.931 is neutral-to-weak, indicating the stock is not oversold enough to signal a strong rebound. Moving averages are converging, which usually points to a sideways or indecisive trend. The short-term pattern data also leans negative, with projected weakness over the next week and month. Overall, the technical picture is not supportive of a confident long-term entry right now.
Truist recently raised its price target to $78 from $76 and maintained a Buy rating, citing stronger Q1 results, an improved outlook, scale, and a diversified revenue base. JPMorgan also initiated coverage with an Overweight rating and a $50 target, noting the stock is trading near a 10-year trough adjusted EBITDA multiple. These are meaningful valuation and recovery catalysts. Option sentiment is also leaning bullish, with low put-call ratios.
There was no news in the past week to drive fresh momentum. Insiders have been selling, and the selling amount increased 1220.79% over the last month, which is a major negative signal. Hedge funds are neutral, and there is no recent congress trading data. The technical trend is weak, and the stock is trading below the pivot with downside nearby. The short-term pattern outlook is also negative.
Latest quarter financial data was not available due to a snapshot error, so a full financial assessment cannot be made from the provided data. The most relevant fundamental clue is analyst commentary that referenced stronger Q1 results and a better outlook, which suggests recent operational improvement. Since the latest quarter season is Q1, the available information points to some growth momentum, but not enough concrete data was provided to verify revenue, earnings, or margin trends directly.
Recent analyst trend is constructive. On 2026-05-01, Truist raised its target to $78 from $76 and kept a Buy rating, highlighting stronger Q1 results and a better outlook. On 2026-04-14, JPMorgan initiated coverage with an Overweight rating and a $50 target, though it cut the target sharply from $83, reflecting a more cautious but still positive view. Wall Street’s pro case is valuation recovery, scale, diversified revenue, and an insurance recovery setup. The con case is AI-related disintermediation risk and the fact that one major firm reduced its target substantially, implying limited conviction in a full rerating. Overall, analysts are still net positive, but the range of targets shows some uncertainty.
